Galantamine ER

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., University of Pennsylvania, Sheppard Pratt Health System

Conditions

Alzheimer's DiseaseNicotine AddictionSchizoaffective DisorderSchizophrenia

Phase 2

Effect of Galantamine on Smoking Abstinence

CompletedNCT01548638

University of PennsylvaniaNicotine Addiction

Start: 2012-02-29End: 2013-10-31Updated: 2017-12-26

Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

TerminatedNCT02234752

Sheppard Pratt Health SystemSchizoaffective Disorder, Schizophrenia

Start: 2014-09-30End: 2016-07-31Updated: 2017-11-09

Phase 3

Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

CompletedNCT00082602

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Alzheimer's Disease

Start: 2004-05-31End: 2005-04-30Updated: 2011-05-20